首页> 美国卫生研究院文献>Molecular Therapy. Nucleic Acids >Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1 Ngn3 and MafA Transcription Factors
【2h】

Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1 Ngn3 and MafA Transcription Factors

机译:胰腺外分泌细胞AR42J重编程为使用Pdx1Ngn3和MafA转录因子的mRNA的胰岛素生产细胞。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Direct reprogramming of pancreatic nonendocrine cells into insulin-producing β-cells represents a promising approach for the treatment of insulin-dependent diabetes. However, its clinical application is limited by the potential for insertional mutagenesis associated with the viral vectors currently used for cell reprogramming. With the aim of developing a nonintegrative reprogramming strategy for derivation of insulin-producing cells, here, we evaluated a new approach utilizing synthetic messenger RNAs encoding reprogramming transcription factors. Administration of synthetic mRNAs encoding three key transcription regulators of β-cell differentiation—Pdx1, Neurogenin3, and MafA—efficiently reprogrammed the pancreatic exocrine cells into insulin-producing cells. In addition to the insulin genes expression, the synthetic mRNAs also induced the expressions of genes important for proper pancreatic β-cell function, including Sur1, Kir6.2, Pcsk1, and Pcsk2. Pretreating cells with the chromatin-modifying agent 5-Aza-2′-deoxycytidine further enhanced reprogramming efficiency, increasing the proportion of insulin-producing cells from 3.5 ± 0.9 to 14.3 ± 1.9% (n = 4). Moreover, 5-Aza-2′-deoxycytidine pretreatment enabled the reprogrammed cells to respond to glucose challenge with increased insulin secretion. In conclusion, our results support that the reprogramming of pancreatic exocrine cells into insulin-producing cells, induced by synthetic mRNAs encoding pancreatic transcription factors, represents a promising approach for cell-based diabetes therapy.
机译:将胰腺非内分泌细胞直接重编程为产生胰岛素的β细胞代表了一种治疗胰岛素依赖型糖尿病的有前途的方法。然而,其临床应用受到与当前用于细胞重编程的病毒载体相关的插入诱变的潜力的限制。为了开发用于产生胰岛素的细胞的非整合重编程策略,在这里,我们评估了一种利用编码重编程转录因子的合成信使RNA的新方法。编码3种β细胞分化的关键转录调节因子(Pdx1,Neurogenin3和MafA)的合成mRNA的施用有效地将胰腺外分泌细胞重编程为产生胰岛素的细胞。除胰岛素基因表达外,合成的mRNA还诱导了对胰腺β细胞正常功能重要的基因的表达,包括Sur1,Kir6.2,Pcsk1和Pcsk2。用染色质修饰剂5-Aza-2'-脱氧胞苷预处理细胞可进一步提高重编程效率,将胰岛素产生细胞的比例从3.5%±0.9%增至14.3%±1.9%(n = 4)。此外,5-Aza-2'-脱氧胞苷预处理可使重编程的细胞对葡萄糖激发反应增加胰岛素分泌。总之,我们的结果支持由编码胰腺转录因子的合成mRNA诱导的胰腺外分泌细胞重编程为产生胰岛素的细胞,代表了基于细胞的糖尿病治疗的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号